RxDoctor Payments Data

Sharon Mayers, APRN

Family · Myrtle Beach, SCNPI 1255972253

Payments from drug & device makers

$5,311in general payments, 2019–2025

Across 96 payments — averaging $55.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Solventum Corporation$2K
  • Phathom Pharmaceuticals, Inc.$499
  • Lilly USA, LLC$481
  • AbbVie$421
  • AstraZeneca$323
  • Novo Nordisk$293
  • plus $2K from 24 others

What the payments were for

  • Travel & lodging$76014%
  • Food & beverage$4,45284%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,311 in reported general payments places this provider in the 90th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$143,542
Medicare patients
262
Services billed
1,724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide13$16,495
EliquisApixaban13$10,158
Triamcinolone Acetonide147$2,149
Gabapentin24$459
Silver Sulfadiazine16$448
Doxycycline Hyclate23$326
Nystatin24$276
Pantoprazole Sodium19$273
Famotidine22$261
Cephalexin18$250
Omeprazole18$247
Atorvastatin Calcium53$246
Rosuvastatin Calcium18$245
Ibuprofen12$238
Duloxetine Hcl15$236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Olanzapine$481$16,59428 claims
PfizerEliquis$16$10,15813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,248 family providers in South Carolina.

Other family in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →